NDAC Veterans Join DSaRM Advisory Panel For DXM Safety Meeting
This article was originally published in The Tan Sheet
Executive Summary
The presence of Nonprescription Drug Advisory Committee members as temporary voters on FDA's Drug Safety and Risk Management Advisory Committee brings expertise on OTC issues and a potential industry advocate to the Sept. 14 meeting on dextromethorphan abuse
You may also be interested in...
FDA Panel Says Leave DXM Unscheduled For Now, Urges Congressional Action
Dextromethorphan likely will escape scheduling as a controlled substance in the near term, but manufacturers and lawmakers should push efforts to curb abuse to keep the cough suppressant available OTC in the long run
DXM Panel Proposes Augmenting, Improving Education To Curb Abuse
Members of an FDA panel tipped their hats to the Consumer Healthcare Product Association's efforts to reduce dextromethorphan abuse, but floated enhancements to the program
FDA Risk Panel DXM Meeting Raises Stakes on Age Restriction Movement
A Drug Safety and Risk Management Advisory Committee meeting scheduled for Sept. 14 on the potential for abuse of the cough suppressant dextromethorphan could bring the OTC industry's next regulatory nightmare